Suppr超能文献

切除的胰腺导管腺癌淋巴结状态的亚分期具有很强的预后相关性:对TNM分期中N分类修订的建议。

Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM Staging.

作者信息

Basturk Olca, Saka Burcu, Balci Serdar, Postlewait Lauren M, Knight Jessica, Goodman Michael, Kooby David, Sarmiento Juan M, El-Rayes Bassel, Choi Hyejeong, Bagci Pelin, Krasinskas Alyssa, Quigley Brian, Reid Michelle D, Akkas Gizem, Maithel Shishir K, Adsay Volkan

机构信息

Department of Pathology, New York University, New York, NY, USA.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1187-95. doi: 10.1245/s10434-015-4861-0. Epub 2015 Sep 11.

Abstract

BACKGROUND

The current tumor-node-metastasis staging system for the pancreas does not incorporate the number of lymph nodes (LNs) with metastasis.

METHODS

Among 1649 pancreaticoduodenectomies, 227 stringently defined pancreatic ductal adenocarcinomas (PDACs) that had undergone a specific approach of LN harvesting were analyzed for the prognostic value of LN substaging protocols used for other gastrointestinal (GI) organs.

RESULTS

The median number of LNs harvested was 18, and the median number of LNs with metastasis was 3. Lymph node metastasis was detected in 175 cases (77 %). The number of LNs involved correlated significantly with clinical outcome. When cases were substaged with the protocol already in use for the upper GI organs (N0: no metastasis, N1: metastasis to 1-2 LNs; N2: metastasis to ≥3 LNs), the median overall survival times were 35, 21, and 18 months, and the respective 3-year survival rates were 46, 34, and 20 % (p = 0.004). Analysis of the Surveillance, Epidemiology and End Results (SEER) database also confirmed the survival differences between these substages (median overall survival times of 23, 15, and 14 months and respective 3-year survival rates of 37, 22, and 18 %; p < 0.0001). The substaging protocol for the lower GI organs (N0: no metastasis; N1: metastasis to 1-3 LNs; N2: metastasis to ≥4 LNs) also was significant, with median overall survival times of 35, 21, 18 months and respective 3-year survival rates of 46, 26, and 23 %; p = 0.009). The association between higher N stage and shorter survival persisted with multivariate modeling for both protocols, although the prognostic value of the upper GI protocol appeared to be slightly stronger according to the Akaike Information Criterion method.

CONCLUSION

In conclusion, with proper LN harvesting, the LN metastasis rate in PDACs is very high (77 %). Substaging of LN metastasis has significant prognostic value and needs to be considered in the N staging of PDACs. The protocol already in use for other upper GI tract organs, which currently also is proven significant for ampulla, would be preferable, although the lower GI tract protocol also is applicable.

摘要

背景

目前用于胰腺的肿瘤-淋巴结-转移分期系统未纳入有转移的淋巴结数量。

方法

在1649例胰十二指肠切除术中,对227例经过特定淋巴结清扫方法的严格定义的胰腺导管腺癌(PDAC)进行分析,以评估用于其他胃肠道(GI)器官的淋巴结亚分期方案的预后价值。

结果

清扫的淋巴结中位数为18个,有转移的淋巴结中位数为3个。175例(77%)检测到淋巴结转移。受累淋巴结数量与临床结局显著相关。当按照用于上消化道器官的方案进行亚分期时(N0:无转移;N1:转移至1-2个淋巴结;N2:转移至≥3个淋巴结),中位总生存时间分别为35、21和18个月,3年生存率分别为46%、34%和20%(p = 0.004)。对监测、流行病学和最终结果(SEER)数据库的分析也证实了这些亚分期之间的生存差异(中位总生存时间分别为23、15和14个月,3年生存率分别为37%、22%和18%;p < 0.0001)。用于下消化道器官的亚分期方案(N0:无转移;N1:转移至1-3个淋巴结;N2:转移至≥4个淋巴结)也具有显著性,中位总生存时间分别为35、21、18个月,3年生存率分别为46%、26%和23%;p = 0.009)。两种方案的多变量建模均显示较高的N分期与较短的生存之间存在关联,尽管根据赤池信息准则方法,上消化道方案的预后价值似乎略强。

结论

总之,通过适当的淋巴结清扫,PDAC的淋巴结转移率非常高(77%)。淋巴结转移亚分期具有显著的预后价值,在PDAC的N分期中需要考虑。目前已证明对壶腹也有显著意义的用于其他上消化道器官的方案可能更可取,尽管下消化道方案也适用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验